This Solicitation opportunity from Government of Canada was posted on January 13, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

ACAN-Botulinum Antitoxin Heptavalent

Closed

WS5474605028International

Submission Closed01/13/2026, 02:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414

New

DIBBS

ANTIVENIN, SNAKE VENOM, PAN-AFRICA

Solicitation # SPE2DP-27-Q-0009

This solicitation, SPE2DP-27-Q-0009, is a small business set-aside request for quotations issued by the DLA Troop Support Medical Supply Chain Pharm FSA for the procurement of Pan-Africa polyvalent F(ab)2 immunoglobulin fragments (equine) antivenin. The product is designed to treat snakebite envenomation caused by 25 different species from the Viperidae, Elapidae, Colubridae, and Atractaspididae families. The requirement is for 6 cases, with each case containing 36 vials (6 vials per box, 6 boxes per case). The item is a Type I (Code Q) item with a non-extendable shelf life of 36 months and must be stored at room temperature. The contract is a firm fixed price agreement with delivery required 15 days after order. Shipping is FOB Destination, and the material must be marked according to Medical Marking Standard No. 1, which supersedes MIL-STD-129. Packaging must be commercial, utilizing suitable sealed unit containers and exterior shipping containers to prevent damage, with palletization following RP001 DLA Packaging Requirements and MIL-STD-2073-1E. Payment and receiving reports must be processed electronically via the Wide Area WorkFlow (WAWF) system. The procurement incorporates various FAR and DFARS clauses, including requirements for cybersecurity safeguarding, anti-terrorism awareness, and the Buy American and Balance of Payments Program.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Вакцина проти сказу, ліофілізат (порошок), 2,5 МО/доза - ДК 021:2015: 33600000-6 Фармацевтична продукція

Solicitation # UA-2026-11-10-011224-a

This contract is a solicitation issued by the Shumska City Hospital under the Government of Ukraine for the procurement of an inactivated whole virus rabies vaccine in lyophilized powder form, with a dosage of 2.5 IU per dose. The procurement is categorized under pharmaceutical products and requires the goods to be delivered in a single shipment based on the customer's specific order. A critical condition of the agreement is that the goods cannot originate from the Russian Federation, the Republic of Belarus, or the Islamic Republic of Iran. The solicitation was posted on November 10, 2026, with a response deadline of November 13, 2026. Performance of the contract will take place in Shumska, Ternopil Oblast, Ukraine.

Комунальне некомерційне підприємство Шумської міської ради "Шумська міська лікарня"

POSTED

DEADLINE

Вакцина для профілактики грипу суспензія для ін'єкцій по 0.5 мл

Solicitation # UA-2026-11-09-008084-a

This solicitation, issued by the Bozhedarivka Center for Primary Health Care under the Government of Ukraine, is for the procurement of influenza prevention vaccines in 0.5 ml injection suspensions. The tender, identified by solicitation number UA-2026-11-09-008084-a, was posted on November 9, 2026, with a response deadline set for November 13, 2026. The performance of the contract will take place in the village of Bozhedarivka, Dnipropetrovsk region. A critical requirement of this contract is the restriction on the country of origin for the supplied goods. Bidders must confirm that the proposed vaccines do not originate from the Russian Federation, the Republic of Belarus, or the Islamic Republic of Iran. Submission of a proposal serves as formal confirmation of compliance with these origin restrictions.

КОМУНАЛЬНЕ НЕКОМЕРЦІЙНЕ ПІДПРИЄМСТВО "БОЖЕДАРІВСЬКИЙ ЦЕНТР ПЕРВИННОЇ МЕДИКО-САНІТАРНОЇ ДОПОМОГИ" БОЖЕДАРІВСЬКОЇ СЕЛИЩНОЇ РАДИ

POSTED

DEADLINE

Trivalent Seasonal Influenza Vaccine Production (SH 2027)This subcontract involves the manufacture and supply of trivalent Seasonal Influenza Virus Vaccines for the Southern Hemisphere 2027 season to support prime contractors fulfilling UNICEF supply contracts. The selected provider is responsible for the entire production cycle, including bulk production, formulation, filling, and labeling. Acceptable manufacturing methods include egg-based, cell culture, recombinant protein, or nucleic acid-based processes, provided the facility possesses the necessary bioreactors or egg-incubation infrastructure and maintains WHO Pre-qualification. The scope of delivery requires the provision of 2,250 10-dose vials and 100 1-dose vials. Performance for this contract will take place across multiple destinations to meet the distribution needs of the agency. The opportunity was posted on November 9, 2026, under NAICS code 325414.

POSTED

DEADLINE

Seasonal Influenza Virus Vaccine, Southern Hemisphere Influenza Season 2027 Luis Roberto Mena - [email hidden]

Solicitation # RFP-DAN-2026-503974

UNICEF is soliciting proposals under RFP-DAN-2026-503974 for the supply of WHO pre-qualified 2027 Southern Hemisphere seasonal influenza vaccines. The objective is to secure quality supplies for the earliest possible delivery in 2027 to meet forecasted demand. Vaccines must meet specific composition requirements for H1N1, H3N2, and B/Victoria lineage strains. Pricing must be quoted based on INCOTERMS 2020 FCA at the nearest international airport, with standard payment terms of net 30 days via bank transfer. Bidders must be registered in the United Nations Global Marketplace and submit a proposal consisting of separate technical and commercial volumes. Technical evaluation is conducted in collaboration with the WHO, focusing on WHO pre-qualification, delivery lead times, and proven past performance. Strict packaging and labeling standards are required, including compliance with WHO Guidelines on the International Packaging and Shipping of Vaccines and mandatory GS1-barcoding on secondary packaging. Suppliers are responsible for the classification of dangerous goods and must provide all necessary Material Safety Data Sheets.

POSTED

DEADLINE

Реагенти для лабораторії імуногенетичних технологій та біоінженерії – ДК 021:2015 – 33690000-3 - Лікарські засоби різні (КЛІТИННА ЛІНІЯ Nalm-6-Zellen – Код ДК 021:2015 – 33696500-0 - Лабораторні реактиви (НК 024:2023/НК 031:2024 – 30670 - Лінія клітинної

Solicitation # UA-2026-11-06-013516-a

The National Children's Specialized Hospital Okhmatdyt of the Ministry of Health of Ukraine is soliciting bids for the procurement of laboratory reagents, specifically the Nalm-6 cell line, for the Laboratory of Immunogenetic Technologies and Bioengineering. This solicitation, identified by number UA-2026-11-06-013516-a, is categorized under various medical and laboratory reagent codes. The performance of the contract and delivery of goods will take place in Kyiv, Ukraine. Interested parties must submit their responses by the deadline of November 22, 2026. A critical compliance requirement for this contract is that the goods provided cannot originate from the Russian Federation, the Republic of Belarus, or the Islamic Republic of Iran. Primary contact for this procurement is Maryna Yakymchuk.

Державне некомерційне підприємство «Національна дитяча спеціалізована лікарня «Охматдит» МОЗ України»

POSTED

DEADLINE

ITB- Supply and delivery of AHS veterinary vaccines [email hidden]

Solicitation # 2026/FNSDN/FNSDN/138908

The Food and Agriculture Organization of the United Nations is seeking offers for the procurement and delivery of AHS veterinary vaccines to Chad. This solicitation, identified as 2026/FNSDN/FNSDN/138908, is managed by the FAO procurement team in Sudan. Interested bidders must possess at least a UNGM Basic Registration with FAO to participate. All offers must be submitted exclusively through the UNGM portal to be considered valid, as any submissions made through other channels will be invalidated.

POSTED

DEADLINE

MEDICAL PHARMACY EMERGENCY NON NSN ORDER

Solicitation # SPE2DP-26-R-0004

Solicitation SPE2DP-26-R-0004 is a Request for Proposal issued on November 4, 2026, by the Department of Defense Medical Supply Chain Pharmacy FSA for the procurement of egg-free Influenza Virus Vaccine, 2027-2028 Formula for adults aged 18 and older. The government intends to award a Firm Fixed Price, Indefinite Delivery, Indefinite Quantity contract to the responsible offeror determined to be most advantageous based on price and non-price factors. Proposals must be submitted electronically via the DIBBS system by December 3, 2026. Award criteria include the proposed unit and total price, agreement to all solicitation terms without exception, and, for large businesses, the submission of a Small Business Subcontracting Plan. The contract mandates strict quality and cold chain management standards, requiring vaccines to be maintained between 2 to 8 degrees Celsius during transportation for up to 72 hours with no acceptable excursions. Products must be delivered to DLA Distribution Susquehanna in New Cumberland, Pennsylvania, and must have an expiration date no later than 18 months after the date of issue from the manufacturer's cold storage. Manufacturers must be FDA current Good Manufacturing Practice acceptable. Packaging and marking must adhere to Medical Marking Standard No. 1D and MIL-STD-129 for perishables. Invoicing and payment will be processed electronically through the Wide Area Workflow system.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

MEDICAL PHARMACY EMERGENCY NON NSN ORDER

Solicitation # SPE2DP-26-R-0003

Solicitation SPE2DP26R0003 is a request for Injectable Influenza Vaccine 2027 issued by the Department of Defense through DLA Troop Support, based in Philadelphia, Pennsylvania. This procurement falls under NAICS code 325414. The solicitation was posted on November 4, 2026, with a response deadline of December 3, 2026, at 8:00 PM. Primary contact for this effort is Rosbert Jones, with Melissa Rios Thomas serving as the secondary point of contact. Proposals must be submitted electronically via the DIBBS system in accordance with FAR 15.208(a). Submissions are subject to strict technical requirements, including a maximum file size of 10 MB per document and a 60-character limit for file names. File names must not contain spaces and may only use hyphens or underscores as special characters. Acceptable file formats include standard document, image, and spreadsheet extensions such as .pdf, .docx, and .xlsx.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Вакцина для профілактики грипу суспензія для ін'єкцій по 0.5 мл

Solicitation # UA-2026-11-04-002309-a

The Government of Ukraine, specifically the Dnipro Center for Primary Health Care No. 9, is soliciting bids for the procurement of influenza prevention vaccines in 0.5 ml injection suspensions. This solicitation, identified by number UA-2026-11-04-002309-a, was posted on November 4, 2026, with a response deadline set for November 20, 2026. The performance of the contract will take place in Dnipro, Dnipropetrovsk region. A critical requirement for participants is the confirmation that the proposed goods do not originate from the Russian Federation, the Republic of Belarus, or the Islamic Republic of Iran. Interested parties may coordinate with the primary point of contact, Olena Vitaliivna Chayka, regarding the submission of price proposals for this medical procurement.

Комунальне некомерційне підприємство "Дніпровський центр первинної медико-санітарної допомоги № 9" Дніпровської міської ради

POSTED

DEADLINE

iPSC Culture and Differentiation

Solicitation # 75N98027Q00053

The National Institutes of Health, specifically the National Institute of Environmental Health Sciences, intends to award a firm-fixed-price purchase order to Creative Biolabs Inc. for iPSC culture and differentiation services. The scope of work involves culturing, differentiating, and expanding cell populations to over 20 million cells, followed by collection and verification. This effort supports a long-term study to sequence and analyze the complex 4q35 locus on Chromosome 4 using Nanopore Sequencing technology. The government is pursuing a sole-source acquisition because Creative Biolabs is identified as the only provider capable of following the specific required protocols and managing the necessary volume of cell lines within a three-month differentiation window. While the intent is to award to a single source, interested parties may submit capability statements to the designated point of contact by November 13, 2026, to demonstrate their ability to meet the technical and operational requirements.

National Institutes Of Health Olao

POSTED

DEADLINE

Scalable Biologic Manufacturing and FormulationThis subcontract focuses on the development of CMC strategies and scalable production processes for biologic therapies supporting prime contractors on NIH/NINDS projects. The scope of work involves utilizing bioreactors and cleanroom facilities to establish manufacturing processes and formulation strategies, ensuring that all quality attributes are validated in accordance with GMP and regulatory standards for clinical application. The successful provider will be responsible for delivering comprehensive scalable manufacturing documentation, formulated drug products, and detailed quality specifications. This effort is managed under the National Institutes of Health within the Department of Health and Human Services, falling under NAICS code 325414 for biologic product manufacturing.

National Institutes Of Health

POSTED

9 days ago

DEADLINE

in almost 2 years

AI Contract Overview

The Government of Canada, through the Department of Public Works and Government Services, has issued solicitation WS5474605028 for the manufacture and storage of Botulinum Antitoxin Heptavalent. The scope of work includes the production and storage of both the Bulk Drug Substance and the finished dosage form of the antitoxin. This federal procurement opportunity is designated for performance within Canada. Interested parties should direct inquiries to the primary point of contact, Kim-Andre Duplin-Vu, with the response deadline set for January 13, 2026.